Medical Oncologist
Molecular Testing Results
How to Read Your — Molecular Pathology Report
A molecular pathology report can run to ten pages or more, and waiting for results from a comprehensive gene panel can feel like a long time when treatment decisions depend on them. The part that matters for your treatment is usually a single paragraph. This guide helps you find it, read it, and know what to ask.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Start with the summary — The final impression or summary section tells you whether an actionable finding was found — read that before anything else.
- Result language varies by lab — Positive, detected, amplified, and high can all describe the same kind of finding. The comparison below maps the most common terms.
- Not all findings change treatment — A positive result only opens a treatment option if a therapy exists for that specific finding in your cancer type and stage.
- VUS is not a diagnosis — A variant of uncertain significance is not the same as a cancer-causing mutation. Most are treated as negative until more evidence exists.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
A molecular pathology report has four sections: sample details, the markers tested, individual results, and a summary. Read the summary first — it says whether an actionable change was found. Then check each marker result to see which targeted treatments, if any, may apply to your cancer.
What does each result term on this report mean?
| Result term | What it means | What happens next |
|---|---|---|
| Positive / Detected | A mutation, fusion, or gene change was found | Your oncologist checks whether an approved treatment targets this specific change in your cancer type and stage |
| Negative / Not detected | No change was found in the tested gene or protein | This narrows options but does not close them — chemotherapy, immunotherapy, or other treatments may still apply |
| High / Low (e.g. PD-L1, TMB) | A measured value above or below the laboratory's reporting threshold | Informs whether immunotherapy is likely to be considered alongside your other results and your cancer type |
| Amplified / Overexpressed | Extra gene copies or excess protein was detected | May indicate a treatment that targets the pathway driven by that gene |
| Variant of uncertain significance (VUS) | A gene change was found, but its effect on cancer behaviour is not yet established | Usually treated as negative for treatment purposes until the evidence base grows |
| Insufficient / Low tumour content | Too little cancer tissue in the sample to give a reliable result | Your oncologist may request a repeat biopsy or a liquid biopsy to complete the picture |
What should I do before my appointment?
- Turn to the summary or impression section and read it before anything else.
- Circle every result labelled positive, detected, amplified, high, or MSI-H.
- Write down every term you do not understand — bring the list to your appointment.
- Note whether the report mentions a VUS and ask your oncologist whether it changes anything.
- Check the sample adequacy section — if tumour content is flagged as low, ask whether the results are reliable.
- Ask which results are actionable for your specific cancer type and stage, not in general.
- Ask whether any finding should be confirmed with a second test before your treatment plan changes.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Did you know?
A comprehensive NGS panel can test hundreds of genes and return many findings, but for most patients only one or two results — sometimes none — will change the treatment plan.
The number of findings on the page does not tell you how many treatment options you have.
Source: NCCN Biomarker Compendium; ASCO Molecular Testing Guidelines
What does my specific result mean for my treatment?
What if the report says Positive or Detected next to a gene name?
A positive result means a change was found in that gene. It does not automatically mean a targeted treatment is available. Your oncologist will check whether the specific change — not just the gene name — has an approved therapy for your cancer type. Some mutations in the same gene respond to targeted drugs while others do not. Ask: 'Is this finding actionable for my cancer, and is there an approved drug for it in India?'
What if every result says Negative or Not detected?
A fully negative molecular panel means no targetable mutation was found in the genes tested. This is a real result with clinical meaning — it tells your oncologist which pathways are not driving your cancer and rules out treatments that would not help you. It does not mean you are without options. Chemotherapy, immunotherapy, or other approaches may still apply, and the decision moves to those options.
What if the report mentions a variant of uncertain significance (VUS)?
A VUS means a gene change was found that has not been studied enough to know whether it drives cancer growth. Most VUS findings do not change treatment at the time they are reported. Your oncologist will typically treat it as a negative result for now. Databases of VUS findings are updated regularly, so a result that is uncertain today may be reclassified as evidence matures. Ask your oncologist whether it is worth monitoring over time.
What if the report shows MSI-H or High TMB?
MSI-H means the tumour shows microsatellite instability — a sign that the tumour's DNA repair system is faulty. High TMB means many mutations have accumulated. Both findings are associated with a pattern of tumour biology that checkpoint inhibitor immunotherapy is designed to target, across a range of cancer types. Whether immunotherapy is recommended also depends on your cancer type, stage, and general fitness. Ask your oncologist whether these findings make you a candidate.
What if the report shows a result my oncologist has not mentioned?
Bring it up directly. Not every finding on a comprehensive panel is discussed at a single appointment, particularly if the most clinically relevant results dominated the conversation. Some positive findings may not be actionable for your specific cancer type. Others may be relevant to clinical trials even when no approved drug exists. Ask: 'Is there anything else on this report that is worth acting on, or that I should keep in mind as my treatment progresses?'
What if the report says the sample was insufficient or the tumour content was low?
An insufficient result means the laboratory could not get a reliable answer because there was too little tumour tissue in the sample, or the DNA was degraded. This is not a negative result — it means the question has not been answered yet. Your oncologist may request a repeat biopsy from the same or a different site, or a liquid biopsy, which tests tumour DNA circulating in the blood. Ask what the next step is and how long it is likely to take.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How long does a molecular pathology report take?
Turnaround varies significantly by test type. A standard IHC panel for markers such as PD-L1 or HER2 is considerably faster than a comprehensive NGS gene panel, which can take several weeks from when adequate tissue reaches the laboratory. Ask your oncologist which tests have been ordered and when results are expected — you should have a timeline, not an open-ended wait.
Can I get a second opinion on my molecular pathology report?
Yes. Reports can be sent to a second laboratory for re-analysis, particularly when the result is a VUS, when sample adequacy is borderline, or when a treatment decision rests on a single finding. A new biopsy is usually not needed — the original tissue block or slides are generally sufficient. Ask your oncologist whether a second opinion is warranted given your specific results.
What is the difference between a mutation and a variant of uncertain significance?
A mutation, in the way most oncology reports use the term, refers to a gene change with known clinical consequences — either driving the cancer or conferring sensitivity to a treatment. A VUS is a gene change whose consequences are not yet well enough established to be classified either way. The distinction matters because a confirmed mutation may open a treatment option, while a VUS is held in a watching position until the evidence base grows.
Does a positive result mean I will receive a targeted drug?
Not automatically. A positive result is a necessary condition for targeted therapy — not a sufficient one. The specific change found must have an approved treatment for your cancer type and stage. Some mutations carry approved drugs in one cancer type but not another. Your oncologist will cross-reference your findings against current CDSCO approvals and available clinical trials to see which options are actually open to you.
Should I bring someone with me when I collect the results?
Yes, if at all possible. Molecular results are detailed, the conversation is often fast, and the terminology is unfamiliar. A second person helps you catch what was said, write down terms to look up later, and think of questions you might forget under pressure. If that is not possible, ask whether the appointment can be recorded, or ask your oncologist to write down the key findings before you leave.
What does molecular pathology testing cost?
Costs vary considerably depending on the test type — a single-marker IHC panel, a small targeted panel, and a large NGS panel are priced very differently — and on whether testing is done at a government centre, a private laboratory, or an accredited reference laboratory. Any figure quoted without knowing your specific test and centre should be treated as indicative only. Ask for the cost of each specific test before the sample is sent.